Literature DB >> 15642808

Cone damage in patients receiving high-dose irofulven treatment.

Michael S Lee1, Nisha Gupta, Richard T Penson, John Loewenstein, Meredith S Wepner, Michael V Seiden, Ann H Milam.   

Abstract

OBJECTIVES: To describe the clinical, perimetric, and electroretinographic (ERG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient's retinas.
DESIGN: Observational case series.
METHODS: The patients were examined clinically, including perimetric and ERG evaluations. Eyes from patient 1 and healthy postmortem eyes were processed for histopathologic and immunocytochemistry studies with antibodies specific for cones, rods, and reactive Müller cells. MAIN OUTCOME MEASURES: Clinical signs and symptoms, perimetry, ERG, retinal histopathologic and immunocytochemistry study results.
RESULTS: All 4 patients had ERG changes consistent with abnormal cone responses and relatively normal rod responses. Compared with control eyes, the retina of patient 1 had approximately half the normal numbers of macular cones and fewer peripheral cones. The number of rods were normal but all rod and cone outer segments were shortened.
CONCLUSION: High-dose irofulven treatment causes cone-specific damage with relative sparing of rods.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642808     DOI: 10.1001/archopht.123.1.29

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  2 in total

1.  A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.

Authors:  Russell J Schilder; John A Blessing; Mark S Shahin; David S Miller; Krishnansu Sujata Tewari; Carolyn Y Muller; David P Warshal; Scott McMeekin; Jacob Rotmensch
Journal:  Int J Gynecol Cancer       Date:  2010-10       Impact factor: 3.437

2.  A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.

Authors:  Werner Hilgers; Sandrine Faivre; Stéphanie Chieze; Jérôme Alexandre; François Lokiec; François Goldwasser; Eric Raymond; Carmen Kahatt; Abdelkrim Taamma; Garry Weems; John R MacDonald; Jean-Louis Misset; Esteban Cvitkovic
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.